Geneos Wealth Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Geneos Wealth Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-24	Closed	-$1K	–	2599
2019 Q3	$1K	Hold	24	–	–	﹤0.01%	2458
2019 Q2	$2K	Hold	24	–	–	﹤0.01%	2354
2019 Q1	$3K	Hold	24	–	–	﹤0.01%	2198
2018 Q4	$3K	Hold	24	–	–	﹤0.01%	2154
2018 Q3	$5K	Buy	24 +7	+41%	+$1.66K	﹤0.01%	2082
2018 Q2	$3K	Sell	17 -7	-29%	-$1.87K	﹤0.01%	2071
2018 Q1	$5K	Hold	24	–	–	﹤0.01%	1875
2017 Q4	$7K	Hold	24	–	–	﹤0.01%	1757
2017 Q3	$8K	Hold	24	–	–	﹤0.01%	1657
2017 Q2	$8K	Buy	24 +17	+243%	+$5.09K	﹤0.01%	1617
2017 Q1	$2K	Hold	7	–	–	﹤0.01%	1941
2016 Q4	$1K	Hold	7	–	–	﹤0.01%	2023
2016 Q3	$1K	Buy	+7	New	+$1.46K	﹤0.01%	1948

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LFAS

Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geneos Wealth Management's DMK Position: Q4 2019 in Review

Geneos Wealth Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2019, closing a stake of 24 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in DMK in Q3 2016 and held it in 13 quarters. The position peaked at $8K in Q3 2017. 38 funds tracked by Wall St. Rank hold DMK as of Q4 2019.

Geneos Wealth Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2019 after selling out during the quarter.
Geneos Wealth Management sold 24 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2019, an estimated $1K.
Geneos Wealth Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2016 and held it in 13 quarters.
Geneos Wealth Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $8K in Q3 2017.
38 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2019.

Based on Geneos Wealth Management's 13F filing for Q4 2019, filed 7 Sep 2021.